2020 - A Year Full Of Potentials, page-192

First 192 Last

Share
Profile

Follow
Sector

35,472 Posts.

2863

11/02/20

18:40

Post #: 42870393
Share

Originally posted by benelong: ↑

OK, I'm reneging. I said I wouldn't come here again. But some of @Sector's posts are so wrong that I feel forced to respond.
I will continue to come here for the same reason I came here in the first place. And that is to save less well-informed visitors from the egregious misclaims in too many of @Sector's posts. Every time he flicks my BS meter I'll be back. Get used to me, it could be often.

So, the manure for the day is "Macdonald said this put Cynata ahead of the pack in terms of commercial product development."
To be fair to Sector, he's quoting someone else. But he expects Macdonald's untruth to be believed here.

Fact is, CYP isn't even in the pack. It doesn't have a product in commercial development. It has something that might become a product in several years time, currently at an early stage of investigation. Nothing proven. Just well founded hope.

People who have read my earlier posts in this thread would know I invest in MSB. Not yet in CYP. I don't come here to trumpet MSB.

If Sector hadn't come dozens of times to MSB threads to trumpet CYP superiority I would never have heard of him or CYP.

So, if I counter Macdonald's false claim by saying that MSB already has a product on sale in Japan via licensee and another licensed to others for sale in Europe (ahead of the pack), it really is for the purpose of making sure that visitors here do not have their investment decisions warped by BS.

I am impressed by the potential of CYP technology. It might make product production cheaper. There's lots of possible hitches between that potential and biotech producers actually wanting to buy it. I'll gladly invest if these uncertainties fade.

@Sector, it would really be appreciated if your replies to my posts reflected my politeness and respect, stuck to facts and avoided puerile insults. People are watching.

Expand

Hahahahaaa, that was fast. Mr Gen 1 Policeman

look who's nervous. and barking up the wrong stem cell tree to boot.

Last edited by Sector: 11/02/20

CYP Price at posting: $1.09 Sentiment: Buy Disclosure: Held
9 Upvote

4 Great analysis

Reply

Top Stories

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

There are more pages in this discussion • 316 more messages in this thread...

First 192 Last

Add CYP (ASX) to my watchlist

(20min delay)
Last 25.0¢		Change 0.000(0.00%)		Mkt cap ! $44.90M

Open	High	Low	Value	Volume
25.5¢	26.0¢	24.5¢	$19.72K	78.84K

Buyers (Bids)

No.	Vol.	Price($)
2	31298	24.5¢

Sellers (Offers)

Price($)	Vol.	No.
25.0¢	39430	1

View Market Depth

No.	Vol.	Price($)
2	31298	0.245
4	112215	0.240
2	119148	0.235
2	15173	0.230
1	20000	0.225

Price($)	Vol.	No.
0.250	39430	1
0.260	25384	1
0.290	1900	1
0.295	183892	1
0.300	85000	2

Last trade - 15.59pm 09/07/2024 (20 minute delay)

CYP (ASX) Chart

2020 - A Year Full Of Potentials, page-192

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

2020 - A Year Full Of Potentials, page-192

Top Stories

Patagonia looks to raise $2.15M for South American exploration and development

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News